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Poly (lactide‑co‑glycolide) (PLGA) nanoparticles (NPs) are biodegradable carriers that participate in the transport of neuroprotective 
drugs across the blood brain barrier (BBB). Targeted brain‑derived neurotrophic factor (BDNF) delivery across the BBB could provide 
neuroprotection in brain injury. We tested the neuroprotective effect of PLGA nanoparticle‑bound BDNF in a  permanent middle 
cerebral artery occlusion (pMCAO) model of ischemia in rats. Sprague‑Dawley rats were subjected to pMCAO. Four hours after pMCAO, 
two groups were intravenously treated with BDNF and NP‑BDNF, respectively. Functional outcome was assessed at 2 and 24 h after 
pMCAO, using the modified neurologic severity score (mNSS) and rotarod performance tests. Following functional assessments, rats 
were euthanized blood was taken to assess levels of the neurobiomarkers neuron‑specific enolase and S100 calcium‑binding protein β 
(S100β), and the brain was evaluated to measure the infarct volume. The NP‑BDNF‑treated group showed significant improvement in 
mNSS compared with pMCAO and BDNF‑treated groups and showed improved rotarod performance. The infarct volume in rats treated 
with NP‑BDNFs was also significantly smaller. These results were further corroborated by correlating differences in estimated NSE and 
S100β. NP‑BDNFs exhibit a significant neuroprotective effect in the pMCAO model of ischemia in rats.
Key words: ischemia, neuroprotection, BDNF, brain infarct volume, neurological deficits, rotarod test, grid‑walking test, neuron specific 
enolase, S100β protein
INTRODUCTION
Stroke remains a major health burden as the sec‑
ond leading cause of death worldwide, according to 
data published in 2012 by the World Health Organiza‑
tion. Annually, 15 million people worldwide suffer from 
stroke. Of these, 5 million die and another 5 million are 
left permanently disabled, placing the burden of care 
on the family and community (World Health Organiza‑
tion, 2002).
Stroke constitutes approximately 2 ‑ 4% of total 
health care costs worldwide and accounts for more 
than 4% of direct health care costs in industrialized 
countries (Ga et al., 2008). Although the incidence and 
prevalence rates of stroke are decreasing in developed 
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countries, the opposite trend is occurring in Asia Pa‑
cific, which has seen an increase in diagnosis of acute 
stroke (Aziz et al., 2015).
Clinically, stroke can be defined as an umbrella of 
conditions caused by the occlusion or haemorrhage 
of cerebral blood vessels supplying the brain (Lo et 
al., 2003). In both cases, stroke ultimately involves the 
death and dysfunction of neuronal cells and neurologi‑
cal deficits that reflect the location and size of the com‑
promised brain area (Lo et al., 2003). To date, the only 
available treatment for acute ischemic stroke (AIS) 
patients with severe neurological deficits is to restore 
blood flow to the ischemic tissue with reperfusion ther‑
apies (Tsivgoulis et al., 2014). However, current ther‑
apies for AIS are inadequate, and the only approved 
medical therapy for AIS is tissue plasminogen activator 
(tPA), a thrombolytic agent that targets the thrombus 
within the blood vessel.
Neuroprotection remains one of the holy grails of 
AIS therapy. The ability to protect the ischemic brain 
from injury until reperfusion and also protect the 
brain from reperfusion injury could theoretically pre‑
vent disability in stroke survivors (Patel and McMul‑
len, 2017). In the past, many neuroprotective agents 
showed efficacy in a variety of animal models of stroke, 
including 5‑HT1A agonists, free radical scavengers, im‑
munosuppressants, and excitotoxicity‑blocking agents. 
However, despite efficacy in rodent models, most have 
failed in clinical trials (Mergenthaler and Meisel, 2012). 
Therefore, establishing new, effective neuroprotective 
strategies for AIS is an urgent concern.
One of the most promising neuroprotective agents 
is brain‑derived neurotrophic factor (BDNF). BDNF is 
a neurotrophic protein that belongs to the neurotro‑
phin protein family and is essential for central nervous 
system (CNS) development, neuronal survival, and neu‑
ronal plasticity (Han et al., 2013). It is the most preva‑
lent growth factor in the CNS. Intracerebroventricular 
(ICV) infusion of BDNF was found to be neuroprotec‑
tive in a permanent middle cerebral artery occlusion 
(pMCAO) model, provided that the ICV infusion of neu‑
rotrophin was initiated 24 hours prior to the ischemic 
insult (Schäbitz et al., 1997). Since it is necessary for 
BDNF to defuse from cerebrospinal fluid (CSF) into the 
layers of the brain following ICV infusion, BDNF is not 
neuroprotective without a significant lead‑time before 
the ischemic insult. It is not practical to administer 
BDNF by ICV infusion for the treatment of AIS, much 
less 24 h before the ischemic insult. Neurotrophin 
needs to be delivered to the ischemic regions within 
the neuroprotective window period, which may be ac‑
complished through the development of intravenous‑
ly (IV) administered nanoparticle‑based technologies 
that deliver BDNF after the ischemic insult.
The use of polymeric nanoparticles (NPs) as drug 
carrier to cross the blood brain barrier (BBB) and de‑
liver BDNF to target cells will revolutionize the medical 
field. This technology could be applied to other neuro‑
logical conditions, such as hypoxic ischemic insults, de‑
pression, Parkinson’s disease, and Alzheimer’s disease, 
in which BDNF has been proven beneficial using in vivo 
experiments (Nagahara and Tuszynski, 2011). Many 
studies have evaluated the effect of BDNF in hypoxic 
ischemia. Thus, it was beneficial to assess if BDNF could 
be neuroprotective against hypoxic ischemic injury 
in an ischemic stroke model (Chen et al., 2012; 2013a; 
2013b; Han et al., 2013). Therefore, we designed BD‑
NF‑loaded poly (lactic‑co‑glycolic acid) (PLGA) NPs and 
studied the neuroprotective effects of PLGA NP‑bound 
BDNF in a pMCAO model of ischemia in rats.
METHODS
Animals 
Twenty‑eight adult male Sprague‑Dawley rats (250 g 
– 300 g) aged 8 to 10 weeks were obtained from the Lab‑
oratory Animal Care Unit of the Universiti Teknologi 
MARA (UiTM), Sg. Buloh Selangor. The animals were 
group‑housed in plastic cages. The rats were placed in 
a room with a 12: 12 light‑dark cycle and controlled tem‑
perature (23 ± 2°C). Food and water were accessible ad 
libitum. Prior to experimentation, rats were allowed to 
adapt to the environment for at least four days. Each rat 
was used once for all experiments. Animal handling and 
testing were carried out according to the procedures 
detailed in the Rodent Stroke Model Guidelines for Pre‑
clinical Stroke Trials (Liu et al., 2009). All experiments 
were approved by the Animal Ethics Committee of the 
Universiti Teknologi MARA (UiTM Care: 119/2015). All 
rats were randomly assigned into four groups (n=7 per 
group), which consisted of sham‑operated (control, 
group 1), stroke (rats with permanent middle cere‑
bral artery occlusion (pMCAO), group 2), BDNF‑treated 
(rats with pMCAO treated with BDNF, group 3), and BD‑
NF‑loaded PLGA NPs (NP‑BDNF) (rats with pMCAO treat‑
ed with NP‑BDNF, group 4) treated group.
Formulation and characterization of BDNF‑loaded 
PLGA NPs
A total number of 10 μg of BDNF in 2 ml of Milli‑Q 
water was poured into a solution of 500 mg of PLGA in 
3 ml dichloromethane solution. The mixture was emul‑
sified using a high shear rotor stator mixer. The ob‑
tained pre‑emulsions were then added to 25 ml of 1% 
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aqueous solution of PVA and the mixture was passed 
through a high‑pressure homogenizer (Next Genera‑
tion Homogeniser, Nano DeBEE, USA) at 2,500 psi for 
3 cycles. Then the organic solvent was removed using 
a magnetic stirrer and the emulsion was left for 24 h. 
Mannitol (5% w/v) was added to the resulting nanosus‑
pension prior to being freeze‑dried for 72 h. The PLGA 
NPs were coated with poloxamer 188 (PLX188) as a sur‑
factant. For coating with PLX188 the lyophilized NPs 
were resuspended in a 0.01% w/v (optimal concentra‑
tion) aqueous solution of PLX188.
The NP‑BDNF was characterized for zeta potential, 
particle size, and morphological appearance. 
NP size and zeta potential (ζ) were measured using 
a dynamic light scattering (DLS) technique (Malvern 
Zetasizer Nano ZS, UK). Approximately 0.3 ml of undi‑
luted NP‑BDNF solution was placed into a clear, dispos‑
able zeta cell, which was then inserted into the Zeta‑
sizer. The experiment was performed at room tempera‑
ture (25°C) with a refractive index (η) of 1.33. 
The morphology of the NP‑BDNF was investigated 
with a transmission electron microscope (TEM) FEI TEC‑
NAI G2 20S TWIN and by environmental scanning elec‑
tron microscopy (ESEM) FEI QUANTA 450 FEG (FEI Ore‑
gon, USA). For TEM, a sample of NPs was suspended in 
water (1mg/1ml). A drop of suspension NPs was placed 
onto parafilm and a copper grid was placed on top of the 
sample. The copper grid was left for 10 min followed by 
the addition of 2% (w/v) uranyl acetate, and then the 
samples were used for imaging. Pictures were taken at 
an excitation voltage of 200kV and a magnification of 
6,000×. As for ESEM, the specimens were coated with 
a Pd‑Au film by an Emitech Magnetron Sputter Coater 
before imaging in order to avoid electric charge build 
up. Pictures were captured at 16,000× magnification. 
The entrapment efficiency (EE) of BDNF encapsu‑
lation in NP‑BDNF was measured after removing ex‑
cess BDNF and separating the particles using a modi‑
fied minicolumn centrifugation method with Sepha‑
dex G‑25 minicolumns. The experiment was repeated 
four times using the following procedure. In brief, Sep‑
hadex G‑25 gel in the columns was allowed to swell with 
PBS for 15 min, followed by centrifugation for 5 min at 
3,000 rpm to remove excess PBS. The dry column was 
loaded with empty PLGA NPs to saturate the column 
and minimize adsorption of actual samples. The loaded 
column was then centrifuged for 15 min at 3,000 rpm 
to expel the excess NPs. Next, NP‑BDNFs were added to 
the column and centrifuged at 3,000 rpm for 15 min to 
separate untrapped BDNF from the NP‑entrapped drug. 
The eluted sample containing entrapped BDNF‑PLGA 
NPs was analysed for BDNF content. For this procedure, 
20% Triton X was added to the sample to destroy PLGA 
NPs. Supernatant aliquots were taken and analysed for 
unbound BDNF using a human recombinant BDNF ELI‑
SA kit, with the absorbance set to 450 nm. The EE was 
calculated using the following formula: 
Induction of ischemia by pMCAO
For this study, all rats were subjected to left side to‑
tal pMCAO, using an intraluminal technique (Belayev 
et al., 1999). Rats were anesthetized with a mixture of 
xylazine (1.5 ml of 100 mg/ml) and ketamine (10 ml 
of 100 mg/ml) given intraperitoneally (0.1 ml/100g 
of body weight). After rats were deeply anesthetized, 
a ventral midline incision was created between the ma‑
nubrium and the jaw on the left side of the neck. Then, 
blunt dissection was used to separate the superficial 
fascia and submandibular glands, and to expose the 
anterior triangle muscles of the neck, i.e., sternohy‑
oid, sternomastoid, and digastric muscles. Once these 
muscles were identified, the blunt dissection was con‑
tinued until the left common carotid artery (CCA) was 
exposed. The proximal area of the CCA and external 
carotid artery (ECA) were permanently ligated using 
5‑0 silk sutures. Meanwhile, the bifurcation of CCA was 
temporarily ligated with a loose knot (Koizumi et al., 
1986). A microvascular clamp was applied to the inter‑
nal carotid artery (ICA). A small arteriotomy was per‑
formed in between the permanent and loose ligation of 
the CCA. In order to create a thrombus or embolic lesion 
to induc e ischemia, a pre‑prepared 4‑0 nylon monofil‑
ament suture was inserted through the opening of the 
arteriotomy and was secured by tightening the loose 
ligation at the artery. Once the loose ligation was tight‑
ened, the microvascular clamp was removed, and the 
4‑0 nylon monofilament suture was rostrally advanced 
until it reached the ICA. The advancement of the suture 
was terminated once resistance was felt. This indicated 
that the blunted end of the suture reached the MCA and 
permanent occlusion was achieved. Finally, the midline 
incision of the neck was sewn with 3‑0 silk using sim‑
ple interrupted sutures. Postoperatively, the rat was 
placed in an individual nursing cage at 37°C to recover 
from the anesthesia. Once the rat regained conscious‑
ness from the surgery, it was then moved to a normal 
cage with ad libitum access to water and food.
Modified Neurological Severity Score (mNSS)
The mNSS test was used to assess impairment in all 
stroke model rats. The mNSS has a defined scoring sys‑
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tem, with 0 as the minimum score and 18 as the max‑
imum score (Chen et al., 2001). After assessments, the 
total score was calculated and the severity of stroke 
was classified as follows: mild injury (1‑6), moderate 
injury (7‑12), severe injury (13‑18), or no neurological 
impairment (0). Thus, the higher the score, the more 
severe the brain injury. The mNSS assesses motor, sen‑
sory, and reflex impairments in animal models after 
ischemic insults (Schaar et al., 2010). Stroke‑induced 
motor deficits were assessed by the grid‑walking test 
(Chao et al., 2010).
The grid‑walking test
The grid‑walking test was used for assessments of 
motor abnormalities in stroke rats. Each rat was placed 
on an elevated, metal, square‑shaped grid unit. Each 
rat’s performance was recorded for 5 min using a vid‑
eo camera (Handycam DCR‑SX22E/B, Sony). A foot slip 
— when the paw completely missed a rung, when the 
limb fell between the rungs, or when the paw was cor‑
rectly placed on the rung but slipped off during weight 
bearing — was considered to be an error of one limb 
climbing the grid. Foot slips and footsteps of the right 
and left forelimbs and hind limbs were counted. The 
motor impairment was expressed as a percentage of 
foot slips over footsteps for each rat. The findings were 
analysed by a person who was blinded to the experi‑
mental groups.
The rotarod performance test
The rotarod performance test was used to assess 
motor function and coordination after brain ischemia 
in rats. It consisted of a rotating rod onto which the 
subject was placed in order to evaluate motor impair‑
ment following brain insult. In this study the rats were 
trained on the rotarod prior to pMCAO. The training 
took three consecutive days, and during the training 
the rats had to perform three rotarod trials in a day 
with 30 min of rest in between the trials (Zhang and 
Pardridge, 2006). The speed of the rod was fixed at 16 
revolutions per min (16 rpm). Any rats that were un‑
able to stay on the rod for at least 200 s were excluded 
from the experiments. Rats were subjected to pMCAO 
on day 4, and on day 5 (24 h after pMCAO) the rats un‑
derwent the rotarod test, including three consecutive 
trials with 30 min of rest in between trials. The results 
were recorded as the average latency in seconds (s) 
(Zhang and Pardridge, 2006). During rotarod assess‑
ment, functional outcomes of the neurological impair‑
ment were recorded using a video camera (Handycam 
DCR – SX22F/B, SONY). A person who was blinded to 
the experimental groups evaluated the findings.
Infarct volume assessment using 
2,3,5‑triphenyltetrazolium chloride (TTC) staining
All rats were euthanized by terminal cardiac punc‑
ture. Prior to the procedure, the rats were anesthetized 
with a mixture of ketamine and xylazine. To reach the 
heart, a midline incision was made from the thoracic 
area down to the abdomen. Then, the abdominal mus‑
cles were separated until the heart was visualized. 
Blood was collected from the left ventricle using a 5 ml 
syringe with 18‑gauge needle. 
The rat was decapitated using a guillotine (NEMI 
Scientific Inc. USA). The brain was extracted and 
chilled in ice‑cold saline (0.9% NaCl) for 2 min. Then, 
the brain was placed on an acrylic brain matrix (Ted 
Pella Inc, USA). Next, five coronal brain sections, 2 mm 
thick, were dissected at + 5, +3, + 1, −1, and −3 anteri‑
or–posterior from the bregma using sterilized dispos‑
able blades. Then, the slices were immersed in 0.05% 
2,3,5‑triphenyltetrazolium chloride (TTC) solution 
(Merck, USA) for 30 min at 37°C in a dark room (Joshi et 
al., 2004). The TTC‑stained brain slices were placed on 
a glass slide. A millimeter scale ruler was placed beside 
the brain section to measure the stain area. The imag‑
es of the slices were captured using a digital camera 
(Lumix DMC‑S5, Panasonic) and analysed using ImageJ 
software (National Institutes of Health, USA). For each 
brain slice, the infarct area (mm2) was estimated, and 
the total infarct volume (mm3) was calculated by multi‑
plying infarcted area by the 2 mm thickness.
The formula for calculating the infarct volume (mm3) 
(Swanson et al., 1990) utilized an indirect method: 
LI = RT – LN
where LI: infarct volume in the left hemisphere as 
measured by the indirect method, RT: total volume 
in the right hemisphere of the same brain, and LN: 
non‑infracted cortex in the right hemisphere of the 
same brain.
Evaluation of S100 calcium‑binding protein β 
(S100β) and neuron‑specific enolase (NSE) levels 
by enzyme‑linked immunosorbent assay (ELISA)
Two neuronal viability markers (NSE and S100β) 
were measured in serum using ELISA (USCN Life Sci‑
ence Inc.) to estimate the degree of cerebral tissue 
damage following pMCAO. 
Serum was obtained from the 2.5 ml of blood col‑
lected by cardiac puncture. Each of the blood samples 
obtained was dispensed immediately in a BD Vacutain‑
er® Rapid Serum Tube. The blood sample was allowed 
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to clot for one hour at room temperature prior to cen‑
trifugation at 1,000 x g for 20 min. The serum was col‑
lected and transferred to a clean tube. The serum was 
stored at ‑80°C until the time of analysis. The protein 
concentration of each serum sample was measured us‑
ing a NanoDrop 1000 spectrophotometer (ND‑1000 by 
Thermo Fisher Scientific, USA) and diluted 10‑fold in 
0.01 mol/L phosphate buffered saline (PBS) at pH 7 pri‑
or to the ELISA.
NSE and S100β standards were prepared by adding 
1 ml of sample/standard dilution buffer into a stan‑
dard tube to make 20 ng/ml of standard solution. After 
a 10‑min incubation at room temperature, the stan‑
dards were mixed thoroughly.
Prior to performing the assay, Horse‑Radish Perox‑
idase (HRP) with Streptavidin‑Biotin Complex (SABC) 
working solutions and 3,3′,5,5′‑Tetramethylbenzidine 
(TMB) substrates were equilibrated for at least 30 min 
at 37°C. The samples and reagents were completely and 
evenly mixed. The standards, test samples, and control 
(zero) wells on the pre‑coated plate were set and record‑
ed, respectively. The plate was washed twice before ad‑
dition of the standards, test samples, and controls. The 
standards and controls were aliquoted into the wells. 
Next, 0.1 ml of sample was added into the appropriate 
wells. The plate was sealed with a cover and incubat‑
ed at 37°C for 90 min. After incubation, the plate con‑
tents were discarded, and the plate was clapped against 
absorbent filter papers or other absorbent materials. 
Next, 0.1 ml of biotinylated detection antibody work‑
ing solution was added into the wells without touching 
the side of the wells. Then, the plate was sealed again 
and incubated at 37°C for 60 min. After the second in‑
cubation, the plate was washed three times with wash 
buffer. After the wash steps, 0.1 ml of SABC solution 
was added into each well, and the plate was again cov‑
ered and incubated at 37°C for 30 min. Then, the cover 
was removed, and the plate was washed for five times 
for one to two min with wash buffer. After 90 µl of TMB 
substrate was added into each well, the plate was cov‑
ered and incubated at 37°C in the dark for 15 to 30 min. 
Finally, 50 µl of Stop Solution was added into each well 
and mixed thoroughly. The OD was read at 450 nm in 
a microplate reader immediately after addition of the 
stop solution.
Statistical analysis 
All results are presented as interquartile range. 
Data were analysed with the statistical package of so‑
cial sciences software (SPSS) 21.0 for Windows (SPSS 
Inc., Chicago, IL). For comparison between multiple 
groups of parametric data, a one‑way analysis of vari‑
ances (ANOVA) was performed, followed by a post‑hoc 
analysis using Bonferroni’s test. For non‑parametric 
data analyses, the Kruskal–Wallis test was performed 
to analyze significant differences between groups, fol‑
lowed by the Mann‑Whitney test to compare between 
two groups separately. The mNSS were analysed using 
the Kruskal–Wallis followed by Mann Whitney test. 
One‑way ANOVA, followed by Bonferroni’s post hoc test, 
were used to analyze motor impairments in the rotarod 
and grid walking tests, infarct volumes, and levels of 
NSE and S100β. Differences at p<0.05 were considered 
statistically significant.
RESULTS 
BDNF‑loaded PLGA NPs
BDNF was incorporated into PLGA NPs, and subse‑
quent coating with PLX188 was confirmed by particle 
size and zeta potential measurement.
Incorporation of BDNF increased the average size 
of the naked PLGA NPs from 27.8 ± 5.28 nm to 106.7 
± 3.42 nm, and the subsequent coating of NPs with 
PLX188 further increased the size to 186.6 ± 19.11 nm 
(Table I). The zeta potential decreased with the proce‑
Table I. Physicochemical parameters of BDNF‑loaded PLGA‑nanoparticles (n=3).
Parameter PLGA NPs BDNF‑loaded PLGA‑nanoparticles (NP‑BDNF)
Mean Particle size (nm)    
Before coating with PLX188 27.8±5.28 106.7±3.42
After coating with 0.01% (w/v) PLX188 160.7±8.41 186.6±19.11
Zeta potential (mV)    
Before coating with PLX188 ‑47.6 ‑20.8
After coating with PLX188 ‑34.3 ‑18.6
Entrapment Efficiency (%)    93%
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dure described above. Drug encapsulation efficiency 
(EE) results demonstrated that BDNF had high loading 
capability into PLGA NPs. PLGA‑NPs had a 93% EE. This 
indicates NP‑BDNFs can act as an improved drug car‑
rier. The enlargement of size and decreasing trend in 
zeta potential compliments each other. Furthermore, 
the trends in size are also supported by the imaging 
results (Fig. 1). 
The morphological characteristics of the NP‑BDNFs 
were observed using ESEM and TEM. The TEM images of 
NP‑BDNFs (Fig. 1D) and empty NPs (Fig. 1B) show that 
the morphology of NPs were generally spherical, with 
particle sizes around 32.3‑200 nm in diameter.
Effect of NP‑BDNF on total brain infarct volumes 
(mm3) of pMCAO‑induced ischemic rats
The IV injection of NP‑BDNFs decreased the infarct 
area of the NP‑BDNF group, as seen in Fig. 2, compared 
Fig.  1. The morphological characteristics of the NP‑BDNFs observed using ESEM and TEM. (A) The ESEM image of PLGA NPs captured at 16,000× 
magnifications. (B) The TEM image of PLGA NPs. Pictures were taken at an excitation voltage of 200kV and a magnification of 6,000×; scale bar=100 nm. 
(C) The ESEM image of BDNF‑encapsulated PLGA NPs after coating with PLX188 captured at 16,000× magnifications. (D) The TEM image of BDNF‑encapsulated 
PLGA NPs coated with PLX188. Pictures were taken at an excitation voltage of 200kV and a magnification of 6,000×; scale bar=100 nm.
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to stroke group and BDNF‑treated group). Following 
TTC staining, the viable tissue was red and the infarct‑
ed area was white (Fig. 2). The sham‑operated group 
showed no infarcted area.
The total brain infarct volumes (mm3) of pM‑
CAO‑induced ischemic rats were estimated by sum‑
ming up the infarct volume of each TTC‑stained 
brain slice (Fig. 3), according to Swanson et al. 
(1990). The overall results showed significant dif‑
ferences among the groups (one‑way ANOVA, post 
hoc Bonferroni’s test, F(3, 24)=123.02, p<0.01). The 
total infarct volume was observed and measured in 
the stroke (204.95 mm3), BDNF‑treated (210.10 mm3), 
and NP‑BDNF‑treated (107.58 mm3) groups (Fig. 3). 
NP‑BDNF‑treated showed a significant 1.9‑fold de‑
crease in infarct volume (p<0.001) after the treat‑
ment with NP‑BDNFs compared to the stroke group. 
When comparing infarct volumes between the BD‑
NF‑treated and NP‑BDNF‑treated groups, only the 
latter had a significantly lower infarct volume, by 
2‑fold (p<0.001), following the treatment. However, 
there was no significant difference between rats in 
BDNF‑treated and stroke group.
Effect of BDNF‑loaded PLGA NP on the functional 
neurological assessment of pMCAO‑induced 
ischemic rats by mNSS
The mNSS test was carried out to assess neurolog‑
ical deficits following pMCAO and after post‑treat‑
ment with either BDNF or NP‑BDNF. The mNSS results 
were analysed using the Kruskal‑Wallis test followed 
by Mann‑Whitney‑U test for pairwise compari‑
sons across all the control and experimental groups 
(F(3,42)=19.091, p<0.01). The mNSS for the degree of 
ischemia in each group was estimated by the total 
score of all three mNSS components: the motor, so‑
matosensory and reflex functions. The highest score 
was observed in the stroke group, which indicated 
that the rats suffered from a severe ischemic stroke. 
The test revealed that the mNSS score was signifi‑
cantly higher in the stroke rats by 14‑fold (p<0.001) 
compared to the sham‑operated rats (Fig. 4). Addi‑
tionally, compared to sham group, the mNSS score was 
significantly higher in the pre‑BDNF and pre‑NP‑BD‑
NF‑treated rats by 15‑ (p<0.001) and 14‑fold (p<0.001), 
respectively, which indicates motor and somatosenso‑
Fig. 2. Effect of BDNF‑loaded PLGA NPs (NP‑BDNFs) on the brain infarct area of pMCAO‑induced ischemic rats. Immediate TTC staining shows 
deep red staining of normal brain tissue and white non‑staining of the infarct tissue with distinct border. Representative TTC stains of coronal 
sections are shown for (A) Sham/control operated, (B) Stroke, (C) Stroke treated with BDNF, and (D) Stroke treated with NP‑BDNF groups. 
The viable tissue is red, while the infarcted area induced by the stroke procedure is white. In the image, group D has less infarcted area than the 
stroke and BDNF‑treated groups.
8 Kamarudin et al. Acta Neurobiol Exp 2020, 80: 1–18
ry dysfunction (Fig. 4). These dysfunctions reflected 
ischemic injuries to the caudoputamen and frontopa‑
rietal cortex regions. Both areas received blood sup‑
ply from the middle cerebral artery and are important 
in motor function, perception, cognition, and spatial 
tasks. The mNSS score remained significantly higher 
in the post‑BDNF‑treated group by 14‑fold (p<0.001), 
and was improved in the post‑NP‑BDNF‑treated group 
by a 7‑fold decrease (p<0.001), when compared with 
sham‑operated rats (Fig. 4). 
Effect of BDNF‑loaded PLGA NPs on 
the hemiparesis of the limbs following 
pMCAO‑induced ischemic stroke
The induction of ischemic stroke in the left hemi‑
sphere of the rat brain by pMCAO resulted in the hemi‑
paresis of the right limbs (contralateral), while the left 
limbs (ipsilateral) were not affected. Latency to fall 
in the rotarod test was significantly lower in stroke, 
pre‑BDNF, and pre‑NP‑BDNF‑treated groups compared 
to the sham‑operated group by 4.7‑ (p<0.001), 4.9‑ 
(p<0.001), and 6.1‑fold (p<0.001), respectively (Fig. 5). 
IV injection of NP‑BDNF four h after pMCAO signifi‑
cantly prolonged the latency to fall from the rotating 
rod by 2.4‑ (p<0.001) and 3.2‑ (p<0.001) fold as compared 
to stroke and pre‑NP‑BDNF‑treated groups, respective‑
ly. The latency to maintain balance on the rotarod was 
2.8‑fold (p<0.001) times higher in the post‑NP‑BDNF 
group than in the post‑BDNF group. There were no sig‑
nificant differences in rotarod performance between 
pre‑ and post‑BDNF‑treated groups (F(5, 36)=407.92, 
p<0.01).
The grid‑walking test was performed to evaluate the 
effect of NP‑BDNF on the hemiparesis of the limbs in 
pMCAO‑induced ischemic rats. The percentage of foot 
slips was recorded for left (ipsilateral) and right (con‑
tralateral) limbs in sham, stroke, stroke post‑treated 
with BDNF, and stroke post‑treated with NP‑BDNF 24 h 
after pMCAO‑induced ischemic stroke. The results for 
each group were represented as the mean percentage 
of total foot slips over total footsteps of the forelimb 
and hind limb. Concurrent with the rotarod test data, 
the NP‑BDNF group showed better performance in the 
grid‑walking test, as the mean percentage of contralat‑
eral foot slips was significantly lower compared to the 
stroke and BDNF post‑treated group.
The stroke group, pre‑BDNF‑treated, and 
pre‑NP‑BDNF‑treated groups showed a higher number 
Fig. 3. Effect of BDNF‑loaded PLGA NPs (NP‑BDNF) on total infarct volumes 
(mm3) of pMCAO‑induced ischemic rats. Notes: Data is expressed as 
interquartile range. The box signifies the upper and lower quartiles, 
and a short black line within the box represents the median. Statistical 
significances were analysed using one‑way ANOVA, followed by the 
Bonferroni post hoc test: n=7; *p<0.001 vs. sham, #p<0.001 vs. stroke, 
@p<0.001 vs. BDNF.
Fig.  4. Effect of BDNF‑loaded PLGA NPs (NP‑BDNF) on modified 
neurological severity scores (mNSS). Notes: Data is expressed as 
interquartile range. The box signifies the upper and lower quartiles, 
and the median is represented by a  short black line within the box. 
Statistical analysis was performed using the Kruskal‑Wallis test followed 
by the Mann‑Whitney U test: n=7, *p<0.001 vs. sham, $p<0.001 vs. 
post‑NP‑BDNF. Pre‑BDNF–stroke rats before receiving BDNF treatment; 
Post‑BDNF–stroke rats after receiving BDNF treatment; Pre‑NP‑BDNF–
stroke rats before receiving NP‑BDNF treatment; Post‑BDNF–stroke rats 
after receiving NP‑BDNF treatment.
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of errors in the right (contralateral) limbs compared to 
sham‑operated rats by 15.1‑ (p<0.001), 15.3‑ (p<0.001), 
and 14.8‑fold (p<0.001), respectively (Fig. 6) (Ipsilateral 
= F(5,36)=3.189, p<0.05; Contralateral = F(5,36)=29.716, 
p<0.01). Stroke rats treated with NP‑BDNF showed 
marked error reduction in the number of right (con‑
tralateral) limb slips compared to stroke group, 
pre‑BDNF‑treated, post‑BDNF‑treated, and pre‑NP‑BD‑
NF‑treated groups by an average of 2‑fold (p<0.001). 
No significant difference was observed in the percent‑
age of left (ipsilateral) foot slips between all the study 
groups (p>0.05) (Fig. 6).
Effect of NP‑BDNF on the concentration of serum 
neurobiochemical markers NSE and S100β 
Effect of NP‑BDNF on NSE levels
NSE is a CNS tissue injury biomarker for brain dam‑
age commonly used in animal and human studies, partic‑
ularly following ischemic brain injury. The stroke, BDNF, 
and NP‑BDNF groups exhibited higher mean NSE levels 
by 17‑ (p<0.001), 17‑ (p<0.001), and 10‑fold (p<0.001), re‑
spectively, compared with the sham group (Fig. 7). 
There was a significant reduction in NSE levels in 
the NP‑BDNF group by 1.68‑fold (p<0.001) compared to 
the stroke group and by 1.7‑fold (p<0.001) compared to 
the BDNF group. However, NSE levels remained signifi‑
cantly higher in the NP‑BDNF group by 10‑fold (p<0.001) 
when compared with the sham group. There was no sig‑
nificant difference in NSE levels between BDNF‑treated 
and stroke rats (p>0.05) (F (3,24)=6193.08, p<0.01).
Effect of NP‑BDNF on S100β levels
S100β is a calcium‑binding protein primarily ex‑
pressed by neuronal tissue. The protein is released 
Fig. 5. Effect of BDNF‑loaded PLGA NPs (NP‑BDNF) on the functional motor 
assessment by the rotarod test. Notes: Data is expressed as interquartile 
range. The box signifies the upper and lower quartiles, and the median is 
represented by a short black line within the box. Statistics were analysed 
using the one‑way ANOVA, followed by the Bonferroni post hoc test. n=7; 
*p<0.001 vs. sham, $p<0.001 vs. post‑NP‑BDNF.
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Fig.  6. Effect of BDNF‑loaded PLGA NPs (NP‑BDNF) on the percentage of contralateral and ipsilateral foot slips 24  h after pMCAO‑induced ischemic 
stroke. Notes: Statistical analysis was performed using the two‑way multivariate ANOVA, followed by the Bonferroni post‑hoc test: n=7; *p<0.001 vs. 
contralateral sham, ^p<0.001 vs. respective ipsilateral, !p<0.001 vs. contralateral post‑NPBDNF; Pre‑BDNF–stroke rats before receiving BDNF treatment; 
Post‑BDNF–stroke rats after receiving BDNF treatment; Pre‑NP‑BDNF–stroke rats before receiving NP‑BDNF treatment; Post‑BDNF–stroke rats after 
receiving NP‑BDNF treatment.
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from cells following neuronal injury and can be detect‑
ed in serum, urine, or CSF with a simple bioassay. It has 
thus been widely investigated as a potential biomarker 
for brain injury. S100β protein levels are significantly 
elevated in cases of traumatic brain injury, neonatal as‑
phyxia, and injury secondary to cardiac arrest, as well 
as other neurodegenerative diseases.
The stroke, BDNF and NP‑BDNF groups exhibit‑
ed higher mean S100β levels by 98.1‑ (p<0.001), 98.6‑ 
(p<0.001) and 58.7‑fold (p<0.001), respectively, com‑
pared to the sham group (Fig. 11). Following treatment, 
there was a significant reduction in S100β levels in the 
NP‑BDNF group by 1.7‑fold (p<0.001) when compared 
with stroke and BDNF‑treated groups (Fig. 8). However, 
S100β levels were significantly lower in the sham‑op‑
erated group by 55‑fold (p<0.001) when compared with 
the NP‑BDNF‑treated group. There was no significant 
difference in S100β levels between the BDNF‑treated 
and stroke groups (p>0.05) (F(3,24)=914.702, p<0.01).
DISCUSSION
This study has demonstrated the effectiveness of 
nanoparticulated BDNF as a neuroprotective agent fol‑
lowing left pMCAO. We found that the reduction in in‑
farct volume demonstrated the neuroprotective effects 
of BDNF after the treatment with NP‑BDNF following 
ischemic injury, as BDNF blocked apoptotic cell death 
in the ischemic penumbra region. The ischemic penum‑
bra consists of neurons that undergo active apoptotic 
death as a result of reduced blood flow to the neuro‑
nal cells. A previous study showed that BDNF exerts its 
neuroprotective effect by preventing caspase‑3‑medi‑
ated apoptosis in ischemic penumbra tissue (Kume et 
al., 1997; Barone and Feuerstein, 1999; Han et al., 2000).
For the first objective, the principal finding of this 
study was a significant reduction in infarct volume in 
the pMCAO stroke group treated with NP‑BDNF, more so 
than in the other groups.  This finding is in agreement 
with a previous study (Yamashita et al., 1997), Schäbitz 
et al., 1997). Meanwhile, the expression of BDNF was 
significantly increased in the peri‑infarct cortices of 
MCAO‑induced mice treated with direct AT2‑receptor 
(AT2R) stimulation with the non‑peptide AT2R‑ago‑
nist compound 21; this was correlated with a reduced 
infarct volume and significantly decreased number of 
apoptotic neurons in the peri‑infarct cortex of the mice 
(Schwengel et al., 2016). BDNF is a well‑known neuro‑
trophic agent with pleiotropic effects. It exerts its ef‑
fects on brain function, including neuroprotection, 
vascular remodelling, neurogenesis, neuronal survival, 
and neuroplasticity, following injury to brain cells, par‑
ticularly after ischemic insults (Chao, 2003; Ohira and 
Hayashi, 2009; Lu et al., 2013). Additionally, BDNF reg‑
ulates neuronal survival, cell migration, and synaptic 
function (Thoenen, 1995; Murer et al., 2001; Baydyuk 
and Xu, 2014; Lu et al., 2014; Meng et al., 2019). 
 Another observation from this study was that both 
the stroke and BDNF‑treated stroke groups showed ex‑
tensive cerebral infarct volumes. these results are con‑
sistent with recent studies on pMCAO rat models, (Park 
Fig. 7. Effect of BDNF‑loaded PLGA NPs (NP‑BDNF) on NSE serum levels 
in pMCAO‑induced ischemic rats. Notes: Data are presented as mean 
± SD. Statistics were analysed using the one‑way ANOVA, followed by the 
Bonferroni post hoc test: n=7, *p<0.001 vs. sham, $p<0.001 vs. NP‑BDNF.
Fig. 8. Effect of BDNF‑loaded PLGA NPs (NP‑BDNF) on S100β concentration 
in serum. Notes: Data are presented as Mean ± SD. Statistics were analysed 
using the one‑way ANOVA, followed by the Bonferroni post hoc test: n=7, 
*p<0.001 vs. sham, $p<0.001 vs. NP‑BDNF.
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et al., 2014) and 200 mm3 (Kim et al., 2014). On the other 
hand, a slightly higher infarct volume (370 mm3) was 
observed when the ischemic stroke rats were induced 
with a 90‑min transient MCAO (Wang et al., 2010). Typ‑
ically, induction of MCAO leads to cell death predom‑
inantly in the striatum and extends into the parietal, 
temporal and frontal cortex areas. In addition, damage 
was also observed in the thalamus, hypothalamus, and 
substantia nigra (Garcia et al., 1995; Kanemitsu et al., 
2002; Williams et al., 2004). In the same way, the brain 
damage of ischemic stroke rats in the present study 
covered a wide area of the striatum and cerebral cor‑
tex, starting from the rostral to the midline frontal cor‑
tex. Subsequently, widespread damage involving these 
brain areas was expected to manifest as disturbances to 
motor function, coordination, and somatosensory defi‑
cits as previously shown in behavioral studies.
Treatment with NP‑BDNF significantly reduced 
areas of brain death, which were mainly located in 
the dorsolateral cortex that covers the striatum. Pri‑
or studies have described a consistent pattern of 
MCAO‑induced cell death, which initially begins with 
striatal infarction and progresses towards the dorsolat‑
eral cortex that covers the striatum (Liu et al., 2009; 
Popp et al., 2009; Ejaz et al., 2013). One group report‑
ed the progression of the ischemic core and penumbra 
region following MCAO‑induced stroke in a rat model 
that started at the spatiotemporal region (Carmichael, 
2005). This present study hypothesizes that treatment 
with NP‑BDNF provides neuroprotection that could 
salvage neuronal cells in the ischemic penumbra area, 
which lies mainly in the cortical region surrounding 
the ischemic core of the striatum.
The infarct volume is calculated based on the differ‑
ences between red and white areas of the brain cortex 
after TTC staining. Although the TTC technique is com‑
mon and convenient, a potential drawback has been de‑
scribed. Several studies have reported the occurrence 
of overlapping areas between viable and infarcted re‑
gions within the TTC‑stained brain slices, which could 
result in inaccurate measurement of the total infarct 
volume (Garcia et al., 1996; 1997; Baron et al., 2014). De‑
spite the limitations of the TCC‑derived infarct volume, 
as a major marker of MCAO outcome in stroked rats its 
measurements of functional recovery reflect outcome 
better than infarct volume (Albers et al., 2001). 
In the present investigation, IV administration of 
BDNF alone had no neuroprotective effect in regional 
brain ischemia. These results are in agreement with 
a study by Zhang and Pardridge in which saline‑treat‑
ed pMCAO animals showed no significant difference in 
infarct volume (2001). However, BDNF alone does have 
a neuroprotective effect following direct ICV adminis‑
tration (Yamashita et al., 1997), when the BBB is by‑
passed, or with IV administration in stroke models that 
have a disrupted BBB. 
Lee et al. (2014) emphasized the importance of the 
duration of the arterial occlusion to stroke outcomes. 
They demonstrated that a 60‑min transient occlusion 
produced moderate stroke severity, while a longer pe‑
riod, such as occlusion for 90 min, caused severe neuro‑
logical deficits in rats (Lee et al., 2014). It is reasonable, 
then, to hypothesize that the neurological deficits seen 
in the 90‑min transient MCAO were due to severe brain 
insults triggered by a longer occlusion as well as injury 
from the subsequent reperfusion. The cerebral damage 
in the 60‑min transient MCAO model was equal to that 
of the permanent MCAO model and was less than the 
damage observed in the 90‑min occlusion Moreover, 
previous studies demonstrated that pMCAO induces 
moderate neurological impairment, with a mean total 
mNSS score between 4 and 7 points using the 14‑point 
scale (Chen et al., 2005; Oron et al., 2006; Boltze et al., 
2012; Sun et al., 2015) and 10 points using the 18‑point 
scale (Zhang et al., 2004; Li et al., 2005). Similarly, oth‑
er studies demonstrated that a 60‑min transient MCAO 
(Lee et al., 2012; Park et al., 2012; Lee et al., 2014) result‑
ed in moderate stroke symptoms, with the mean total 
mNSS score between 8 and 11 points using the 18‑point 
scale. The area of MCAO‑induced cerebral infarction is 
often confined between the caudoputamen, temporal 
and occipital lobes, frontoparietal cortex, and a number 
of subcortical structures, such as the hypothalamus, in 
rats (Garcia et al., 1995; Kanemitsu et al., 2002). Hence, 
it is evident that pMCAO of the left‑brain hemisphere 
induced moderate focal neurological impairments that 
mainly caused motor and somatosensory deficits, as re‑
flected by the mNSS, without affecting other functions, 
such as reflexes and myoclonic movement.
NP‑BDNF‑treated ischemic rats demonstrated 
a mild form of stroke, as indicated by improved neu‑
rological functions and mNSS scores, compared to un‑
treated stroked rats. On the other hand, BDNF‑treated 
ischemic rats demonstrated a moderate form of stroke, 
similar to untreated ischemic rats. To date, many stud‑
ies have explored the role of BDNF as a neuroprotective 
agent, particularly during ischemic insults. As in previ‑
ous studies, we noted a reduction in stroke volume and 
an improvement in functional outcomes following de‑
layed IV administration of BDNF in regional brain isch‑
emia (Zhang et al., 2006). Improvement of neurological 
deficits in NP‑BDNF‑treated stroked rats was due to the 
ability of the NPs to carry BDNF across the BBB and ex‑
ert its neuroprotective effects. This result occurred be‑
cause the NP formulation that contained BDNF enabled 
receptor‑mediated transport across an intact BBB in 
vivo (Zhang et al., 2006). Another study by Zensi et al. 
(2009) demonstrated that localization of NPs with co‑
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valently bound apolipoprotein E (Apo E) were detected 
in brain capillary endothelial cells and neurons after IV 
administration of human serum albumin NPs with co‑
valently bound Apo E in mice. These findings indicate 
that NPs with covalently bound Apo E are taken into 
the cerebral endothelium by an endocytic mechanism, 
followed by transcytosis into the brain parenchyma. 
These similar results highlight the significance of the 
surface properties of NPs in successful and efficient 
brain drug delivery. 
In this study PLGA NPs were coated with the PLX188 
surfactant. Surface modification with PLX188 enabled 
the successful NP delivery of BDNF across the BBB. 
The PLX188 coating enhanced the penetration, as con‑
firmed by other studies (Gelperina et al., 2010; Wohlfart 
et al., 2011; Kulkarni and Feng, 2011). Another essen‑
tial point is that coating polymeric NPs with PLX188 
decreases the clearance of NPs by the reticuloendo‑
thelial system thereby increasing the circulation time 
of the compound in the plasma (Moghimi and Hunter, 
2000; Mozafari et al., 2009). This enhances NP delivery 
across the BBB, because the NPs are able to bind to the 
low‑density lipoprotein receptor (LDLR) located on the 
surface of the BBB. 
A number of behavioral assays were performed in 
rats prior to the pMCAO and after treatment either 
with BDNF alone or NP‑BDNF, to confirm the neuro‑
logical deficits associated with cerebral ischemia. Mus‑
cle weakness or motor impairment is a common com‑
plaint after stroke in humans. In this study, the results 
demonstrated a correlation between vestibulomotor 
recoveries, as measured by the rotarod and grid‑walk‑
ing tests, and neurocognitive function, as measured 
by mNSS scores, and showed reduced cerebral infarct 
volumes in animals treated with IV administration of 
NP‑BDNF. 
The severity of motor deficits correlated with the 
extent of cerebral infarction. A reduction in cerebral 
infarction areas resulted in improved functional motor 
recovery. A prior study showed that IV BDNF treatment 
after pMCAO reduced cerebral infarct size and coun‑
terregulated apoptotic proteins, particularly Bax and 
Bcl‑2, after temporary focal cerebral ischemia (Schab‑
itz et al., 2000). Subsequently, many researchers cor‑
related the pathology results with behavior outcomes 
in MCAO models following neuroprotection with BDNF. 
Zhang et al. (2018a) concluded that neuroprotective 
neurotrophins, such as BDNF, improve functional out‑
comes following treatment with DPSCs combined with 
BDNF in rats with focal cerebral ischemia. On the other 
hand, Taliyan and Ramagiri (2016) found that lithium 
treatment upregulated BDNF expression after acute 
ischemic insults, and that this increase correlated with 
improved functional motor assessment in MCAO rats. 
Another study showed that BDNF may modulate local 
inflammation at cellular, cytokine, and nuclear fac‑
tor levels in the brain after MCAO, and that this may 
reduce cellular injury caused ischemic insults and re‑
duce neurologic deficits after stroke (Jiang et al., 2010). 
In the present study, in the pMCAO‑induced ischemic 
stroke rats the rotarod latency significantly increased 
following treatment with NP‑BDNF.
The third assessment, the grid walking or foot 
fault test, was a functional motor assessment to de‑
termine the degree of the hemiparesis (Hernandez 
and Schallert, 1988; Chao et al., 2012). In the present 
study, pMCAO rats exhibited the highest incidence of 
contralateral foot slips, compared to the other groups. 
This data is consistent with previous studies show‑
ing that ischemic animals generally demonstrate sig‑
nificantly more contralateral foot slips than normal 
healthy animals (Schaar et al., 2010). In this study, the 
observation of contralateral foot slips was likely due 
to pMCAO that caused primary motor and somatosen‑
sory impairment, as correlated by the mNSS scores 
and rotarod assessment. This finding was consistent 
with a number of studies, which demonstrated that 
the induction of pMCAO resulted in a significant in‑
crease in contralateral foot slips (Shukla et al., 2006; 
Chen et al., 2005; Rogers et al., 1997a). The duration 
of arterial occlusion also had an impact on the se‑
verity in neurological impairments. A study by Rog‑
ers et al. (1997a), reported the number of contralat‑
eral foot slips in rats with transient MCAO increased 
with the MCAO duration of the ischemic stroke that 
was induced in the left hemisphere of the rat brain; 
therefore, it affected right limb functions and the left 
limbs remained unaffected. In the present study, the 
ipsilateral limbs of stroked rats in each group demon‑
strated significantly lower incidences of foot slips 
compared to contralateral foot slips, indicating that 
the pMCAO procedure successfully induced specific 
focal strokes in the left‑brain and caused hemiparesis 
of only the right limbs. The ischemic stroke rats in all 
groups, except for the sham‑operated group, showed 
no significant difference in latency and frequency 
of movement during the grid‑walking test prior to 
treatment. These results were in concordance with 
the mNSS results that showed that pMCAO induced 
altered latency in ischemic stroke rats with moderate 
to severe ischemia. 
On the other hand, ischemic rats treated with 
NP‑BDNF showed significant improvement in con‑
tralateral limb function; these results suggest that 
NP‑BDNF was effective in rendering sensorimotor cor‑
tex protection against ischemia. Other than assessing 
coordination, the grid‑walking test also assesses grip 
strength, which was not evaluated during the mNSS 
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motor tests. Overall, we postulated that treatment with 
NP‑BDNF induced neuroprotection and restricted the 
spread of the infarction area from reaching the motor 
and somatosensory cortices of the rats.
NSE, or enolase‑2, is a γγ isoenzyme of enolase that 
converts 2‑phospho‑glycerate to phosphoenolpyru‑
vate, and is a glycolytic enzyme predominantly located 
in the cytoplasm of neurons and neuroendocrine cells. 
NSE represents a high percentage (1.5%) of total solu‑
ble brain proteins and is stable in biological fluids. It is 
also present in other non‑neuronal sites, most notably 
erythrocytes. In normal subjects, however, it is only 
found in minor concentrations (Casmiro et al., 2005; 
Gelderblom et al., 2013). For that reason, increased se‑
rum NSE levels are a reliable neurobiomarker of the se‑
verity of neuronal damage and BBB impairment follow‑
ing insults. Many studies using animal stroke models 
have confirmed this significant increase in NSE (Horn 
et al., 1995; Yi et al., 2008; Gelderblom et al., 2013; Guo 
et al., 2014). According to Gelderblom et al. NSE (2013) 
is an exclusive biomarker of neuronal injuries be‑
cause NSE was found in supernatants of lysed neurons 
and was absent in supernatants of lysed glial cells or 
in plasma of normal mice. Moreover, NSE levels were 
highly correlated with levels of lactate dehydrogenase, 
an enzymatic marker of cell death (Gelderblom et al., 
2013). Furthermore, a study by Horn et al. (1995) fur‑
ther strengthened the argument that serum NSE could 
correlate with ischemic neuronal injury. They discov‑
ered that transient, bilateral occlusion for 5 minutes 
resulted in a significant increase in serum NSE concen‑
tration in the Mongolian gerbil ischemic stroke model. 
In addition, leakage of the disrupted BBB was evident 
in hypoxic ischemic rats that also had fewer NSE‑pos‑
itive cells in the cerebral cortex but increased serum 
NSE level (Yi et al., 2008). 
Importantly, NSE is a neurobiomarker that can also 
identify neuronal injury in human subjects who have 
suffered brain insults, including cerebral infarction 
(Cunningham et al., 1991; Çakmak et al., 2014), sub‑
arachnoid hemorrhage (Mabe et al., 1991; Tawk et al., 
2015), and head injury (Skogseid et al., 1992; Chabok et 
al., 2012; Olivecrona et al., 2015). The increased levels 
of blood NSE could be primarily attributed to loss of 
CNS NSE due to nerve damage (Çeltik et al., 2004; Gel‑
derblom et al., 2013; Guo et al., 2014; Bharosay et al., 
2018). 
Tawk and colleagues (2015) found that an increased 
NSE level correlates with poor clinical presentations 
and worse outcomes following subarachnoid hemor‑
rhage. One study demonstrated increasing NSE lev‑
els over several days in a small sample of ischemic 
stroke patients (Persson et al., 1987), and another 
study showed that the magnitude of serum NSE in 
hemorrhagic stroke was higher in patients with poor 
neurological status (Mabe et al., 1991). Moreover, the 
maximum levels of serum NSE detected were cor‑
related with the severity of head injury (Skogseid et 
al., 1992) and cerebral infarct volume (Cunningham 
et al., 1991). 
The disturbance in endothelial tight junctions of 
the BBB around the peri‑infarct zone during trau‑
matic brain injury, such as ischemic stroke, caus‑
es an increase in paracellular permeability (Haley 
and Lawrence, 2017). Due to this event, vascular‑de‑
rived substances were allowed to enter the brain and 
brain‑specific proteins could leak into the circulatory 
system (Sandoval and Witt, 2008). Moreover, the com‑
promised BBB also played a role in the formation of 
edema that, consequently, worsened the neurological 
outcome (Stokum et al., 2016). In addition, another 
study further hypothesized that the ischemia asso‑
ciated with BBB dysfunction did not necessarily de‑
pend on the structural alteration of endothelial tight 
junctions (Krueger et al., 2013) but could also be as‑
sisted by transcellular pathways involving caveolae or 
vacuoles in the endothelium that lead to transcytosis 
of plasma proteins across the BBB (Zhang et al., 2015; 
Nahirney et al., 2016). Additionally, a number of stud‑
ies reported significant correlations between the NSE 
levels in the circulatory system, brain infarction vol‑
umes (Li et al., 2015), and neurological deficits (Zaheer 
et al., 2013; Bharosay et al., 2018). Due to these data, 
an evaluation of BBB integrity is a crucial factor in 
determining the severity and progression of ischemic 
stroke injury. 
In the present study, circulating NSE after cerebral 
artery occlusion was significantly increased in plasma 
following pMCAO‑induced cerebral infarction, but not 
following sham surgery. The increased plasma NSE, 
under these conditions, corresponded to infarct vol‑
ume and neurological impairment assessments, which 
included mNSS, rotarod, and grid‑walking tests. The 
NSE levels were determined 24 h post‑pMCAO induc‑
tion. Following NP‑BDNF treatment, NSE levels were 
significantly lower than in untreated pMCAO rats and 
BDNF‑treated pMCAO rats. Reduced NSE levels correlat‑
ed with the degree of neurological impairments, as as‑
sessed by neurobehavioral activity. IV administration 
with NPs containing neuroprotective agents, such as 
BDNF, resulted in lower NSE levels, reduced stroke vol‑
umes, and improved functional outcomes. 
Similarly, S100β is another neurobiomarker that 
predicts prognosis after acute ischemia and indicates 
effectiveness of neuroprotective treatments (Tanaka 
et al., 2007; Mori et al., 2010). S100β is a glial‑derived, 
calcium‑binding, 21 kDa protein comprised of two 
subunits, A and B, that is involved in multiple intra‑
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cellular processes and functions as a neurotrophic fac‑
tor. S100β is also involved in the regulation of intra‑
cellular and extracellular calcium metabolism. When 
the two subunits combine, they result in S100AB and 
S100BB subtypes. S100AB is predominantly found in 
astrocytes, S100BB is located in both Schwann cells 
and astrocytes, and S100AA is found in striated muscle, 
heart, and kidney (Tanaka et al., 2007). Application of 
S100β in nanomolar concentrations protected neurons 
against apoptosis, enhanced astrocytes, stimulated 
neurite outgrowth, and enhanced survival of neurons 
during development in vitro (Sorci et al., 2013). In con‑
trast, micromolar levels of S100β stimulated nitric 
oxide synthase expression and nitric oxide secretion 
from cultured astrocytes (Hu et al., 1997; Matsui et al., 
2002) and induced proinflammatory cytokines (Kop‑
pal et al., 2001) and neuronal apoptosis (Fulle et al., 
2000; Steiner et al., 2011; Zhang et al., 2018b). S100β 
levels in serum or CSF significantly correlated with 
the brain infarct volume, neurological deficits, and 
functional outcome in patients with ischemic stroke 
and animal models of stroke (Missler et al., 1997; Elt‑
ing et al., 2000; Tanaka et al., 2007; Nash et al., 2008). 
In this study, there was a significant increase in S100β 
levels in pMCAO rats and BDNF‑treated pMCAO rats. 
S100β levels were reduced in NP‑BDNF‑treated rats, 
when compared with sham‑operated rats. These re‑
sults showed there was a significant effect of ischemic 
stroke on the level of S100β in the serum of untreat‑
ed and BDNF‑treated pMCAO rats. A previous study 
found that S100β levels significantly increased 24 h 
after a 60‑min transient ischemic stroke in rats, and 
that S100β levels peaked at 48 h after the stroke. In 
this study, the level of S100β was measured 24 h after 
pMCAO. The elevation of the serum S100β correlated 
with the brain water content 72 hours after pMCAO, 
suggesting that S100β could be a neurobiomarker for 
the formation of brain edema and disruption of the 
BBB (Tanaka et al., 2007). Furthermore, the level of 
S100β at 48 h after MCAO could indicate the severity of 
the neurological impairments measured at 168 h after 
stroke (Tanaka et al., 2007). In the current study, the 
ischemic stroke group showed a significant elevation 
in serum S100β levels, which correlated with the de‑
gree of neurological impairment found in pMCAO and 
BDNF‑treated pMCAO rats. Previous studies have de‑
scribed an association between the level of S100β and 
pathophysiological mechanisms relating to the for‑
mation of vascular injuries, BBB disruption, and ede‑
ma (Tanaka et al., 2007). Numerous studies have also 
proven that samples drawn at later time points estab‑
lish stronger correlations between serum biomarker 
concentrations and clinical or radiographic measures 
(Jauch et al., 2017).
CONCLUSION
This study successfully demonstrated the neuropro‑
tective effect of NP‑BDNF in pMCAO‑induced ischemic 
stroke in rats for the first time. The optimal formula‑
tion, with ideal particle size and less negative surface 
charge, allowed NPs to penetrate the BBB efficiently. 
We found that the total infarct volume and levels of 
neurobiomarkers (NSE and S100β) were significantly 
reduced in rats with pMCAO when NPs were given at 
a BDNF concentration of 50 ng/ml during the window 
period (4 ‑ 6 h) of neuroprotection. Thus, the behav‑
ioral and functional assessment of rats with ischemic 
stroke showed significant improvement after treat‑
ment with NP‑BDNF.
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